| 1. | | Recruiting | Recombinant Human Factor IX (rFIX; BeneFIX®) in Previously Treated Patients (PTPs) with Hemophilia B
Condition: Hemophilia B |
| 2. | | Recruiting | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
Condition: Multiple Myeloma |
| 3. | | Recruiting | ReFacto® in Subjects with Hemophilia A Undergoing Major Surgery
Condition: Hemophilia A |
| 4. | | Recruiting | A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
Condition: Multiple Myeloma |
| 5. | | Not yet recruiting | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma
Condition: Multiple Myeloma |
| 6. | | Recruiting | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
Condition: Multiple Myeloma |
| 7. | | Recruiting | Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 8. | | Recruiting | A Study to Assess SOM230 in Patients with Pituitary Cushing’s Disease
Condition: Cushing's Syndrome |
| 9. | | Recruiting | Study of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
Condition: Multiple Myeloma |
| 10. | | Not yet recruiting | Melphalan and Amifostine Followed By Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: Drug Toxicity; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 11. | | Recruiting | Safety and Efficacy of Atiprimod for Patients with Refractory Multiple Myeloma
Condition: Multiple Myeloma |
| 12. | | Recruiting | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 13. | | Recruiting | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma |
| 14. | | Recruiting | Study Comparing Skeletal Targeted Radiotherapy (STR) plus Melphalan to Melphalan Alone, with Stem Cell Transplant in Multiple Myeloma
Condition: Multiple Myeloma |
| 15. | | Recruiting | Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
Condition: Multiple Myeloma |
| 16. | | Recruiting | Study of Combination PS-341 and Thalidomide in Multiple Myeloma
Condition: Multiple Myeloma |
| 17. | | Recruiting | Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide
Condition: Multiple Myeloma |
| 18. | | Recruiting | Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide
Condition: Multiple Myeloma |
| 19. | | Recruiting | UARK 2003-33, Total Therapy III
Condition: Multiple Myeloma |
| 20. | | Recruiting | Cognition, Steroids, and Imaging in Cushings Disease
Condition: Cushing Syndrome |
| 21. | | Recruiting | Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia |
| 22. | | Recruiting | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma
Condition: Multiple Myeloma |
| 23. | | Recruiting | Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma
Condition: Multiple Myeloma |
| 24. | | Recruiting | CCI-779 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 25. | | Recruiting | Xcellerated T CellsTM in Patients with Multiple Myeloma
Condition: Multiple Myeloma |
| 26. | | Recruiting | Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B
Condition: Hemophilia B |
| 27. | | Recruiting | Bortezomib in Treating Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma
Condition: stage III multiple myeloma |
| 28. | | Recruiting | Tandem Autologous Stem Cell Transplantation With or Without Maintenance Therapy After the Second Transplantation Compared With Autologous Stem Cell Transplantation Followed By Matched Sibling Allogeneic Stem Cell Transplantation in Patients With Stage II or Stage III Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 29. | | Recruiting | Low-Dose Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Allogeneic Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorder or Myelodysplastic Syndrome
Conditions: Polycythemia Vera; Essential Thrombocythemia; de novo myelodysplastic syndromes; previously treated myelodysplastic syndromes; ... |
| 30. | | Recruiting | Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients with Multiple Myeloma
Condition: Multiple Myeloma |
| 31. | | Recruiting | Double Cord Blood Transplant Study
Conditions: Leukemia, Lymphocytic, Acute; Leukemia, Myelocytic, Acute; Leukemia, Myeloid, Chronic; Lymphoma, Non-Hodgkin; Multiple Myeloma |
| 32. | | Recruiting | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 33. | | Recruiting | High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
Conditions: primary systemic amyloidosis; stage II multiple myeloma; stage III multiple myeloma |
| 34. | | Not yet recruiting | Dexamethasone With or Without CC-5013 in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 35. | | Recruiting | A Study of PS-341 Given to Patients With Multiple Myeloma who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
Condition: Multiple Myeloma |
| 36. | | Recruiting | Combined Bone Marrow and Kidney Transplant for Multiple Myeloma with Kidney Failure
Conditions: Kidney Failure, Chronic; Multiple Myeloma |
| 37. | | Recruiting | Safety Study of AP23573 in Patients with Advanced, Refractory or Recurrent Malignancies
Conditions: Tumors; Lymphoma; Multiple Myeloma |
| 38. | | Recruiting | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia |
| 39. | | Recruiting | Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
Condition: Multiple Myeloma |
| 40. | | Recruiting | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
Conditions: adult non-Hodgkin's lymphoma; adult solid tumor; Multiple Myeloma; refractory plasma cell neoplasm |
| 41. | | Recruiting | Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm |
| 42. | | Recruiting | Safety and pharmacokinetics of orally administered gallium maltolate in various refractory malignancies.
Conditions: Prostatic Neoplasms; Multiple Myeloma; Bladder Neoplasms; Lymphoma |
| 43. | | Recruiting | Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 44. | | Recruiting | Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H
Conditions: Myelodysplastic Disorders; Leukemia; Multiple Myeloma; Plasma Cell Dyscrasia; Lymphoproliferative Disorders |
| 45. | | Recruiting | Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia |
| 46. | | Recruiting | Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 47. | | Recruiting | Imatinib Mesylate in Treating Patients With Myelofibrosis
Conditions: Polycythemia Vera; chronic idiopathic myelofibrosis; Essential Thrombocythemia; Chronic Myelomonocytic Leukemia |
| 48. | | Recruiting | Severe Hemophilia B Study
Condition: Hemophilia B |
| 49. | | Recruiting | Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma |
| 50. | | Recruiting | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific |
